Literature DB >> 20881869

Successful treatment of trilateral retinoblastoma with conventional and high-dose chemotherapy plus radiotherapy: a case report.

Maria Antonietta De Ioris1, Paola Fidani, Francis L Munier, Annalisa Serra, Ilaria Ilari, Maya Beck Popovic, Gianluigi Natali, Domitilla Elena Secco, Raffaele Cozza.   

Abstract

Trilateral retinoblastoma (TRB) is a rare condition characterized by an intracranial neuroblastic tumor associated with bilateral or unilateral retinoblastoma (RB). The outcome is almost always fatal. An 18-month-old patient with familial bilateral RB was referred for a pineal lesion detected on a screening by magnetic resonance imaging. The child, considered inoperable by 2 different neurosurgical teams, was treated with conventional chemotherapy (methotrexate, vincristine, vepeside, cyclophosphamide, and carboplatin) plus tandem transplantation (vepeside/carboplatin and thiotepa/mephalan) followed by local radiotherapy. At 80 months from the diagnosis of TRB, the patient is alive and in complete remission, with no neuropsychologic consequences. An early and aggressive treatment may improve the prognosis of TRB.

Entities:  

Mesh:

Year:  2010        PMID: 20881869     DOI: 10.1097/MPH.0b013e3181e90031

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  High-dose chemotherapy followed by autologous and allogeneic peripheral blood stem cell transplantation for recurrent disseminated trilateral retinoblastoma.

Authors:  Toshihisa Tsuruta; Yasuo Aihara; Hitoshi Kanno; Chikako Kiyotani; Katsuya Maebayashi; Masako Sakauchi; Makiko Osawa; Hisaichi Fujii; Osami Kubo; Yoshikazu Okada
Journal:  Childs Nerv Syst       Date:  2011-03-19       Impact factor: 1.475

2.  Trilateral retinoblastoma: A systematic review of 211 cases.

Authors:  Ryuya Yamanaka; Azusa Hayano; Yasuo Takashima
Journal:  Neurosurg Rev       Date:  2017-08-16       Impact factor: 3.042

3.  Trilateral retinoblastoma: neuroimaging characteristics and value of routine brain screening on admission.

Authors:  Firazia Rodjan; Pim de Graaf; Hervé J Brisse; Sophia Göricke; Philippe Maeder; Paolo Galluzzi; Isabelle Aerts; Claire Alapetite; Laurence Desjardins; Regina Wieland; Maja Beck Popovic; Manuel Diezi; Francis L Munier; Theodora Hadjistilianou; Dirk L Knol; Annette C Moll; Jonas A Castelijns
Journal:  J Neurooncol       Date:  2012-07-18       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.